Bukwang recently announced that Ministry of Food and Drug Safety (MFDS) has granted JM-010 for the treatment of levodopa-induced dyskinesia (LID). JM-010 is currently being developed by a CNS specialized bioventure Contera Pharma, a subsidiary of Bukwang.
LID is a movement disorder occurs inevitably in 60~70% of Parkinson’s disease patients who receive long-term levodopa treatment. There is currently no satisfactory treatments for the disabling condition that significantly reduce patients’ quality of life.
JM-010 satisfies the primary endpoints of both efficacy and safety in a proof of concept clinical study in South Africa. In addition, a phase 1 clinical study has recently been completed in Germany, providing pharmacokinetics data that support further development of the drug. With the JM-010 development on the right track, the company is planning to commence Korean phase 2 in the second half of 2017.
“With orphan drug designation, speed of JM-010 development will be accelerated and thus is a good news for patients suffering from LID.” Bukwang’s representative added.